Sarcoma  >>  CMB305  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
CMB305 / Merck (MSD)
IMDZ-C232, NCT02609984: Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (/V943A-002)

Checkmark Study of CMB305 and atezolizumab versus atezolizumab in NY-ESO-1+ soft tissue sarcoma
Jun 2019 - Jun 2019: Study of CMB305 and atezolizumab versus atezolizumab in NY-ESO-1+ soft tissue sarcoma
Hourglass Jul 2018 - Dec 2018 : 18-month survival data of CMB305 + atezolizumab in STS
Hourglass Jun 2018 - Jun 2018 : Data on >1 year survival from trial of CMB305 + atezolizumab in STS at ASCO 2018
Checkmark Interim analysis in STS at SITC 2017 [screenshot]
More
Terminated
2
89
US
CMB305, atezolizumab, TECENTRIQ®
Immune Design, Genentech, Inc.
Sarcoma, Myxoid/Round Cell Liposarcoma, Synovial Sarcoma, Metastatic Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Locally Advanced Sarcoma, Liposarcoma
02/19
02/19

Download Options